Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans
- PMID: 9625268
- DOI: 10.1007/BF03189822
Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans
Abstract
The relationship between plasma concentrations and inhibitory effects on gastric acid secretion by proton pump inhibitors (PPIs) omeprazole (OPZ), lansoprazole (LPZ) and pantoprazole (PPZ), was analyzed using a pharmacokinetic/pharmacodynamic (PK/PD) model in humans. The estimated values of apparent reaction rate constant of PPI and H+,K+-ATPase (K) were 1.34 +/- 0.17 (microM(-1) x h(-1)), 0.339 +/- 0.002 and 0.134 +/- 0.006 for OPZ, LPZ and PPZ, respectively. The estimated values of apparent turn-over rate constant of H+,K+-ATPase (k) were 0.0252 +/- 0.0019 (h(-1)), 0.0537 +/- 0.0006 and 0.0151 +/- 0.0002 for OPZ, LPZ and PPZ, respectively. The apparent dissociation constants of the H+,K+-ATPase-PPI complex (k/K x fp) corrected with plasma free fraction (fp) were about 1 nM for OPZ and LPZ and 2.3 nM for PPZ. Therefore, the potency of the inhibitory effect of PPZ on acid secretion may be slightly weaker than that of OPZ or LPZ. The apparent half lives (ln2/k) of the inhibitory effect on acid secretion were 12.9 h for LPZ, < 27.5 h for OPZ, and < 45.9 h for PPZ, the recovery rate of the inhibitory effect of PPZ on acid secretion was slowest among these PPIs. In conclusion, the relationship between plasma concentrations and inhibitory effects of PPIs on gastric acid secretion could be analyzed by the PK/PD model.
Similar articles
-
Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.Drug Metab Dispos. 1995 Jul;23(7):718-23. Drug Metab Dispos. 1995. PMID: 7587960
-
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002. Clin Pharmacokinet. 1996. PMID: 8827397 Review.
-
Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.J Am Pharm Assoc (Wash). 2000 Jan-Feb;40(1):52-62; quiz 121-3. doi: 10.1016/s1086-5802(16)31036-1. J Am Pharm Assoc (Wash). 2000. PMID: 10665250 Review.
-
Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.Br J Clin Pharmacol. 1998 Apr;45(4):369-75. doi: 10.1046/j.1365-2125.1998.t01-1-00702.x. Br J Clin Pharmacol. 1998. PMID: 9578184 Free PMC article. Clinical Trial.
-
Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.Drug Metab Dispos. 2004 Aug;32(8):821-7. doi: 10.1124/dmd.32.8.821. Drug Metab Dispos. 2004. PMID: 15258107
Cited by
-
Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.Dig Dis Sci. 2017 Sep;62(9):2258-2265. doi: 10.1007/s10620-017-4695-7. Epub 2017 Aug 3. Dig Dis Sci. 2017. PMID: 28776139 Review.
-
The gastric HK-ATPase: structure, function, and inhibition.Pflugers Arch. 2009 Jan;457(3):609-22. doi: 10.1007/s00424-008-0495-4. Epub 2008 Jun 6. Pflugers Arch. 2009. PMID: 18536934 Free PMC article. Review.
-
Gastric H,K-ATPase as a drug target.Dig Dis Sci. 2006 May;51(5):823-33. doi: 10.1007/s10620-005-9042-8. Epub 2006 Apr 28. Dig Dis Sci. 2006. PMID: 16645899 Review. No abstract available.
-
Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.Dig Dis Sci. 2006 Jan;51(1):123-31. doi: 10.1007/s10620-006-3096-0. Dig Dis Sci. 2006. PMID: 16416224 Clinical Trial.
-
Leveraging Omeprazole PBPK/PD Modeling to Inform Drug-Drug Interactions and Specific Recommendations for Pediatric Labeling.Pharmaceutics. 2025 Mar 14;17(3):373. doi: 10.3390/pharmaceutics17030373. Pharmaceutics. 2025. PMID: 40143036 Free PMC article.